Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biogen Idec Inc (BIIB)  
$116.82 4.98 (4.09%) as of 4:30 Tue 5/6


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 153,880,000
Market Cap: 17.98(B)
Last Volume: 1,736,123 Avg Vol: 1,335,119
52 Week Range: $113.38 - $236.8
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 500     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 7.6
Insider 6 Months    : 7.6
Insider 3/6 Months : 15.5
Guru Rank Number :  690
Guru Rank Value     : 3
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co. has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Co. also commercialize biosimilars of biologics and focuses on improving its pipeline in neuroscience and immunology. Co.'s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 1,235 1,235 1,235 1,690
Total Buy Value $151,559 $151,559 $151,559 $252,815
Total People Bought 1 1 1 2
Total Buy Transactions 1 1 1 2
Total Shares Sold 8,760 8,870 9,301 11,439
Total Sell Value $1,314,142 $1,331,435 $1,419,454 $1,943,720
Total People Sold 1 2 2 2
Total Sell Transactions 1 2 3 11
End Date 2025-02-06 2024-11-05 2024-05-07 2023-05-08

   
Records found: 616
  Page 1 of 25  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Dorsa Caroline Director   •       •      –    2025-05-02 4 B $122.72 $151,559 D/D 1,235 27,842 2.39     -
   Keeney Adam Head of Corporate Development   •       •      –    2025-05-01 4 D $120.93 $54,902 D/D (454) 2,384     -
   Keeney Adam Head of Corporate Development   •       •      –    2025-05-01 4 OE $0.00 $0 D/D 938 2,838     -
   Sherwin Stephen A Director   •       •      –    2025-03-07 4 S $150.02 $1,314,142 D/D (8,760) 11,318 18%     
   Godbout Sean Chief Accounting OfficerOffice   •       –      –    2025-03-01 3 IO $0.00 $0 D/D 0 310 -13%     
   Kramer Robin Chief Accounting Officer   •       •      –    2025-02-10 4 D $142.54 $34,922 D/D (245) 8,012     -
   Kramer Robin Chief Accounting Officer   •       •      –    2025-02-10 4 OE $0.00 $0 D/D 834 8,257     -
   Gregory Ginger EVP, Human Resources   •       •      –    2025-02-10 4 D $142.54 $90,370 D/D (634) 17,598     -
   Gregory Ginger EVP, Human Resources   •       •      –    2025-02-10 4 OE $0.00 $0 D/D 2,159 18,232     -
   Alexander Susan H EVP Chief Legal Officer   •       •      –    2025-02-10 4 D $142.54 $115,030 D/D (807) 36,265     -
   Alexander Susan H EVP Chief Legal Officer   •       •      –    2025-02-10 4 OE $0.00 $0 D/D 2,575 37,072     -
   Mcdonnell Michael R EVP, Chief Financial Officer   •       •      –    2025-02-10 4 D $142.54 $195,422 D/D (1,371) 24,341     -
   Mcdonnell Michael R EVP, Chief Financial Officer   •       •      –    2025-02-10 4 OE $0.00 $0 D/D 3,257 25,712     -
   Murphy Nicole Head of Pharm Ops and Tech   •       •      –    2025-02-10 4 D $142.54 $95,502 D/D (670) 14,055     -
   Murphy Nicole Head of Pharm Ops and Tech   •       •      –    2025-02-10 4 OE $0.00 $0 D/D 2,272 14,725     -
   Izzar Rachid Head of Global Product Strat.   •       •      –    2025-02-10 4 D $142.54 $63,430 D/D (445) 8,553     -
   Izzar Rachid Head of Global Product Strat.   •       •      –    2025-02-10 4 OE $0.00 $0 D/D 1,515 8,998     -
   Singhal Priya Head of Development   •       •      –    2025-02-10 4 D $142.54 $50,887 D/D (357) 9,066     -
   Singhal Priya Head of Development   •       •      –    2025-02-10 4 OE $0.00 $0 D/D 1,212 9,423     -
   Izzar Rachid Head of Global Product Strat.   •       •      –    2025-02-07 4 OE $0.00 $0 D/D 3,844 7,860     -
   Izzar Rachid Head of Global Product Strat.   •       •      –    2025-02-07 4 D $141.35 $164,673 D/D (1,165) 6,059     -
   Murphy Nicole Head of Pharm Ops and Tech   •       •      –    2025-02-07 4 D $141.35 $172,871 D/D (1,223) 12,453     -
   Murphy Nicole Head of Pharm Ops and Tech   •       •      –    2025-02-07 4 OE $0.00 $0 D/D 4,042 13,056     -
   Mcdonnell Michael R EVP, Chief Financial Officer   •       •      –    2025-02-07 4 D $141.35 $212,308 D/D (1,502) 22,455     -
   Mcdonnell Michael R EVP, Chief Financial Officer   •       •      –    2025-02-07 4 OE $0.00 $0 D/D 4,551 23,171     -
  616 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 25
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us